𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Therapeutic efficacy and safety profile of infliximab in active systemic lupus erythematosus

✍ Scribed by Sawsan Johar Hayat; Sukhbir Singh Uppal

Publisher
Springer
Year
2007
Tongue
English
Weight
182 KB
Volume
17
Category
Article
ISSN
1439-7595

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Efficacy and safety of rituximab in mode
Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: The randomized, double-blind, phase ii/iii systemic lupus erythematosus evaluation of rituximab trial
✍ Joan T. Merrill; C. Michael Neuwelt; Daniel J. Wallace; Joseph C. Shanahan; Kevi πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 English βš– 499 KB πŸ‘ 2 views

## Abstract ## Objective B cells are likely to contribute to the pathogenesis of systemic lupus erythematosus (SLE), and rituximab induces depletion of B cells. The Exploratory Phase II/III SLE Evaluation of Rituximab (EXPLORER) trial tested the efficacy and safety of rituximab versus placebo in p

Effects of short-term infliximab therapy
Effects of short-term infliximab therapy on autoantibodies in systemic lupus erythematosus
✍ Martin Aringer; GΓΌnter Steiner; Winfried B. Graninger; Elisabeth HΓΆfler; Carl W. πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 150 KB πŸ‘ 2 views

Objective. To analyze changes in autoantibodies occurring in patients with systemic lupus erythematosus (SLE) treated with 4 infusions of the chimeric anti-tumor necrosis factor ␣ (TNF␣) antibody infliximab. Methods. In an open-label safety study, 7 patients with SLE were treated with infliximab at